MRK vs ABT
By Alex · Tickerpine
Merck & Company, Inc. vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | ABT |
|---|---|---|
| Price | $132.92 | $110.91 |
| Market cap | $327.94B | $191.92B |
| P/E ratio | 106.3 | 35.4 |
| ROE | 6.96% | 10.58% |
| Profit margin | 4.77% | 11.65% |
| Revenue growth | 5.10% | 13.00% |
| Dividend yield | 2.56% | 2.27% |
| Beta | 0.21 | 0.58 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs ABT in plain English
- MRK is the bigger company — about 1.7× the market cap of ABT.
- ABT is cheaper on earnings (P/E 35.4 vs 106.3).
- ABT earns a higher return on equity (11% vs 7%).
- ABT is growing revenue faster (13% vs 5%).
- MRK has the higher dividend yield (2.56% vs 2.27%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Company, Inc. would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.